Sanofi’s (SAN FP) Cenrifki recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses

Newsquawk StaffPublished
Newsquawk headlinesUTC

Every headline is on the live feed 20 minutes before this site.

China CSRC vows to strengthen supervision of overseas listing

Hezbollah lawmaker says ceasefire extension “meaningless” in light of Israel’s continued “hostile acts”, according to a statement

Sanofi’s (SAN FP) Cenrifki recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses

SLB (SLB) is expected to announce plans to acquire S&P Global (S&P Global) Energy’s geoscience and petroleum-engineering software business, Bloomberg reports citing sources

ECB's Kazimir says a slight rate increase may be required

On the Newsquawk feed at , 20 minutes before this page.

Use the PlatformFree. No signup, no card.

Context

Sanofi’s Cenrifki receiving a positive recommendation from the CHMP for EU approval is notable as it could significantly enhance their product pipeline in the growing multiple sclerosis market. This approval not only validates their research efforts but may also drive stock performance and investor sentiment, particularly in the pharmaceuticals sector, and could spark further M&A activity as competitors assess their own pipelines.

Related headlines

The feed had this first.

Use the Platform